Using Virtual Reality and AI to Treat Psychosis
RecoVRy - A Randomized Controlled Trial Examining the Effect of Artificial Intelligence Powered Virtual Reality Treatment in Psychosis
This study is testing a new treatment that uses virtual reality and artificial intelligence to see if it can help people with psychosis feel better and improve their daily lives.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 150 (estimated) |
| Ages | 17 Years to 65 Years |
| Sex | All |
| Sponsor | Oslo University Hospital Academic / other |
| Locations | 2 sites (Oslo, Norway and 1 other locations) |
| Trial ID | NCT06728241 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to explore the effectiveness of a novel treatment combining cognitive behavioral therapy-based virtual reality (VR) with advanced artificial intelligence (AI) for patients with psychosis. The study will assess the short- and long-term impacts of the RecoVRy application on psychiatric symptoms, quality of life, and real-world functioning among participants. A total of 150 individuals aged 17 to 65, diagnosed with schizophrenia spectrum psychosis or affective disorders with psychotic symptoms, will be recruited from participating hospital trusts. The trial seeks to address the significant challenges faced by patients, particularly those experiencing anxiety that hinders their daily activities.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 17 to 65 who are receiving treatment for psychosis and experience difficulties engaging in everyday activities.
Not a fit: Patients with primary diagnoses of substance use disorders, personality disorders, or those currently in forensic or intensive care settings may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve the quality of life and functional outcomes for patients suffering from psychosis.
How similar studies have performed: While the use of VR in mental health treatment is gaining traction, this specific combination of VR and AI in treating psychosis is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 17 -65 years of age * Receiving psychosis treatment at either clinic in the participating hospital trusts * A clinical diagnosis of schizophrenia spectrum psychosis according to ICD-10 (F20 - F29) or an affective diagnosis with psychotic symptoms (F31.2, F31.5, F32.3, F33.3) * Self-reported difficulties going outside or taking part in everyday activities * Willing and able to provide written informed consent for participation in the study Exclusion Criteria: * Photosensitive epilepsy * Substantial visual, auditory, or balance impairments * Insufficient comprehension of Norwegian * Currently receiving treatment in a forensic setting or Psychiatric Intensive Care Unit * Primary diagnosis of alcohol or substance use disorder or personality disorder; organic syndrome * Clinically significant learning disability
Where this trial is running
Oslo, Norway and 1 other locations
- Oslo University Hospital — Oslo, Norway, Norway (Recruiting)
- Oslo University Hospital — Nydalen, Norway (Active_not_recruiting)
Study contacts
- Principal investigator: Jan Ivar Røssberg, PhD — Universitetet i Oslo/Oslo universitetssykehus
- Study coordinator: Jan Ivar Røssberg, Professor
- Email: j.i.rossberg@medisin.uio.no
- Phone: +47 47876866
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.